Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles

Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles can cause acute hypersensitivity reactions (HSRs) in a high percentage (up to 45%) of patients, with hemodynamic, respiratory and cutaneous manifestations. The phenomenon can be explained with activation of the complement (C) system on the surface of lipid particles, leading to anaphylatoxin (C5a and C3a) liberation and subsequent release reactions of mast cells, basophils and possibly other inflammatory cells in blood. These reactions can be reproduced and studied in pigs, dogs and rats, animal models which differ from each other in sensitivity and spectrum of symptoms. In the most sensitive pig model, a few miligrams of liposome (phospholipid) can cause anaphylactoid shock, characterized by pulmonary hypertension, systemic hypotension, decreased cardiac output and major cardiac arrhythmias. Pigs also display cutaneous symptoms, such as flushing and rash. The sensitivity of dogs to hemodynamic changes is close to that of pigs, but unlike pigs, dogs also react to micellar lipids (such as Cremophor EL) and their response includes pronounced blood cell and vegetative neural changes (e.g., leukopenia followed by leukocytosis, thrombocytopenia, fluid excretions). Rats are relatively insensitive inasmuch as hypotension, their most prominent response to liposomes, is induced only by one or two orders of magnitude higher phospholipid doses (based on body weight) compared to the reactogenic dose in pigs and dogs. It is suggested that the porcine and dog models are applicable for measuring and predicting the (pseudo)allergic activity of particulate “nanodrugs”.

[1]  S. de Marie Liposomal and lipid-based formulations of amphotericin B. , 1996, Leukemia.

[2]  F. Ligler,et al.  Biological responses to exchange transfusion with liposome-encapsulated hemoglobin. , 1992, Circulatory shock.

[3]  J. Szebeni The Complement System , 2004, Springer US.

[4]  M. Bodó,et al.  The interaction of liposomes with the complement system: in vitro and in vivo assays. , 2003, Methods in enzymology.

[5]  M. Woodle,et al.  Long Circulating Liposomes: Old Drugs, New Therapeutics , 1998, Biotechnology Intelligence Unit.

[6]  J. Szebeni,et al.  The interaction of liposomes with the complement system. , 1998, Critical reviews in therapeutic drug carrier systems.

[7]  W. Lorenz,et al.  Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent , 1977, Agents and Actions.

[8]  G. Feuerstein,et al.  Characterization of hemodynamic, hematologic, and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. , 1989, Circulatory shock.

[9]  J. Uetrecht,et al.  Role of animal models in the study of drug-induced hypersensitivity reactions , 2005, The AAPS Journal.

[10]  D. Tzemach,et al.  Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.

[11]  J Szebeni,et al.  Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. , 1999, Circulation.

[12]  L J Liang,et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J Szebeni,et al.  Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. , 2001, International immunopharmacology.

[14]  J. Szebeni The complement system : novel roles in health and disease , 2004 .

[15]  H. Lutz,et al.  The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) , 2000 .

[16]  J. Szebeni Complement Activation-Related Pseudoallergy , 2004 .

[17]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. V. Von Roenn,et al.  Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F M Muggia,et al.  Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. , 1998, Journal of the National Cancer Institute.

[20]  J. Hainsworth,et al.  Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Bodó,et al.  Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. , 2006, American journal of physiology. Heart and circulatory physiology.

[22]  T. Yue,et al.  Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. , 1990, Circulatory shock.

[23]  Y. Barenholz,et al.  Clinical studies of liposome-encapsulated doxorubicin. , 1994, Acta oncologica.

[24]  A. Giatromanolaki,et al.  Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Pode,et al.  Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer , 2000, Anti-cancer drugs.

[26]  A. Brody,et al.  Pulmonary intravascular macrophages produce prostaglandins and leukotrienes in vitro. , 1988, Chest.

[27]  J. Codina,et al.  Sch-28080 depletes intracellular ATP selectively in mIMCD-3 cells. , 2000, American journal of physiology. Cell physiology.

[28]  M. Olausson,et al.  Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. , 2003, The Journal of surgical research.

[29]  A. Hershey,et al.  Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. , 2004, Journal of veterinary internal medicine.

[30]  A. Gabizon,et al.  Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors , 1998 .

[31]  Thomas Bieber,et al.  Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. , 2004, The Journal of allergy and clinical immunology.

[32]  R. Pieters,et al.  Murine models of drug hypersensitivity , 2005, Current opinion in allergy and clinical immunology.

[33]  J. Weaver,et al.  Clinical relevance of preclinical testing for allergic side effects. , 2005, Toxicology.

[34]  F. Blecha,et al.  Porcine Alveolar and Pulmonary Intravascular Macrophages: Comparison of Immune Functions , 1991, Journal of leukocyte biology.

[35]  C. Alving,et al.  Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. , 1994, Biochemical and biophysical research communications.

[36]  M. Bodó,et al.  Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. , 2000, American journal of physiology. Heart and circulatory physiology.

[37]  M. Bodó,et al.  Complement-Dependent Shock and Tissue Damage Induced by Intravenous Injection of Cholesterol-Enriched Liposomes in Rats , 2003 .

[38]  S. Marie Liposomal and lipid-based formulations of amphotericin B , 1996 .

[39]  J. Szebeni,et al.  Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. , 2001, Critical reviews in therapeutic drug carrier systems.

[40]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Ostensen,et al.  Intravenous injection of Albunex microspheres causes thromboxane mediated pulmonary hypertension in pigs, but not in monkeys or rabbits. , 1992, Acta physiologica Scandinavica.